Curtiss-Wright and Sintavia Deliver First Submarine Component Utilizing an Additively Manufactured Impeller to be Installed in a U.S. Navy Vessel
4.12.2024 13:59:00 CET | Business Wire | Press release
Curtiss-Wright’s EMS Division today announced that it has delivered the first submarine component with an additively manufactured (AM) impeller that will be installed in a U.S. Navy vessel.
Curtiss-Wright’s Engineered Pump Division (EPD) in Bethlehem, PA, Bechtel Plant Machinery Inc. (BPMI) in Monroeville, PA, and Sintavia, LLC in Fort Lauderdale, FL, collaborated to develop, manufacture, test, and supply the first submarine component utilizing a qualified, metal additively manufactured part. Sintavia, a leader in designing and manufacturing critical additively manufactured defense components, provided the AM impeller after a thorough qualification process. This impeller was assembled into the pump and tested at Curtiss-Wright’s facility in Bethlehem, PA.
Additive manufacturing technology offers a solution to the development of a product or component that historically has been difficult or costly to manufacture, often resulting in delays. The use of this technology is expected to provide a reliable and high-quality domestic source while also leading to shorter manufacturing lead times, increased quality, lower risk in performance, and improved delivery to further meet the needs of the U.S. Navy.
“Sintavia has proven to be an invaluable industry partner, and we are excited about the opportunity to further solidify our partnership by increasing the number of additively manufactured parts for this application and other critical naval defense components,” said David Micha, Sr. Vice President and General Manager of the EMS Division. “In addition, we are proud to be providing the first critical service equipment utilizing an additively manufactured component to the U.S. Navy’s submarine program and look forward to expanding these capabilities in the future to more efficiently serve our customer.”
“We would like to thank both Curtiss-Wright and BPMI for the opportunity to leverage Sintavia’s additive technology in the production of this critical component,” said Lindsay Lewis, Sintavia’s Corporate Vice President. “Leading-edge manufacturing processes such as AM will continue to be key differentiators in developing superior defense components in the years to come.”
Curtiss-Wright’s EPD business unit, part of Curtiss-Wright’s EMS division, and its predecessor companies have provided naval and maritime technological expertise and products since 1847. Today, EPD is a leading supplier of pumps and components that meet demanding and mission critical requirements for the world’s surface and submerged naval fleets. EPD also provides a wide range of spare and replacement parts, composite pump components, and support services for complete overhaul, upgrade, and in-field expertise. For more information, please visit www.cw-ems.com/epd.
About Curtiss-Wright Corporation
Curtiss-Wright Corporation is a global integrated business that provides highly engineered products, solutions and services mainly to Aerospace & Defense markets, as well as critical technologies in demanding Commercial Power, Process and Industrial markets. We leverage a workforce of approximately 8,600 highly skilled employees who develop, design and build what we believe are the best engineered solutions to the markets we serve. Building on the heritage of Glenn Curtiss and the Wright brothers, Curtiss-Wright has a long tradition of providing innovative solutions through trusted customer relationships. For more information, visit www.curtisswright.com.
About Sintavia
Sintavia is the world's first all-digital Aerospace & Defense component manufacturer. A founding member of the Additive Manufacturer Green Trade Association, Sintavia is committed to the highest quality standards in the industry and holds multiple Nadcap and other aerospace accreditations. For more information visit www.sintavia.com.
About Bechtel Plant Machinery, Inc.
Bechtel Plant Machinery, Inc. (BPMI) the U.S. Naval Nuclear Propulsion Program provides high quality nuclear power plant components for submarines and aircraft carriers. For more information, visit www.bpmionline.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203011953/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom